An antibody drug that targets a surface marker on cancer stem cells could offer a promising new therapeutic approach for treating acute myeloid leukemia (AML), a form of blood cancer that affects an estimated 50,000 people ...
Sep 23, 2016
0
5
Researchers at Massachusetts General Hospital (MGH) and the Harvard Stem Cell Institute (HSCI) have identified a drug compound that arrests in mice the progression of acute myeloid leukemia (AML), a bone marrow cancer that ...
Sep 16, 2016
0
76
Although targeted drugs like Gleevec have revolutionized the treatment of chronic myelogenous leukemia (CML), patients generally must take them for the rest of their lives and may cease benefiting from them over time. In ...
Sep 15, 2016
0
56
A study in mice combining two inhibitor drugs for treatment of chronic myeloid leukemia (CML) has revealed potential for not only stopping the disease completely, but also significantly lowering the cost for treatment. CML ...
Sep 7, 2016
0
17
A recent study by University of Rochester Medical Center researchers proves why leukemia is so difficult to treat and suggests that the current approach to drug development should be adjusted to target a broader range of ...
Aug 30, 2016
0
0
Researchers at University of California San Diego School of Medicine and Moores Cancer Center have identified RNA-based biomarkers that distinguish between normal, aging hematopoietic stem cells and leukemia stem cells associated ...
Aug 26, 2016
0
40
Across many cancer types, obese patients fare worse than leaner patients. Now a University of Colorado Cancer Center study published in the journal Cell Stem Cell offers a compelling hypothesis why: researchers found that ...
Jul 20, 2016
0
52
When adults develop blood cancer, they are frequently diagnosed with what is referred to as acute myeloid leukemia. The disease is triggered by pathological alterations of bone marrow cells, in which, in addition, an important ...
Jul 14, 2016
0
12
Chronic myeloid leukemia (CML) develops through chromosomal alterations in blood-forming cells of the bone marrow and usually occurs in older persons. Around 20 percent of adults diagnosed with leukemia suffer from this type ...
Jun 20, 2016
0
5
In a randomized Phase III study of the drug inotuzumab ozogamicin, a statistically significant percentage of patients with acute lymphoblastic leukemia (ALL) whose disease had relapsed following standard therapies, qualified ...
Jun 12, 2016
0
3
